- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03906188
Serious Game for Fibromyalgia Patients
Development and Validation of a Serious Game for Fibromyalgia Patients: Pre-experimental Study
Aim: To check the applicability of LitEmotion© in people with Fibromyalgia.
Design: randomized clinical trial, with pre, post and follow-up evaluation. Researchers and outcome evaluator blinded.
Method: The experimental group will play during three weeks to LitEmotion© videogame. The control group will not play.
Study Overview
Detailed Description
The study will be a longitudinal-transversal research work with two groups. Findings will us prove the correlation between a right management of emotions and the perception of pain, daily life activities and quality of sleeping.
Sample will be selected by following strict rules; people with no requirements will be dismissed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Burgos, Spain, 09003
- Universidad de Burgos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fibromyalgia diagnosed
- Referred pain during the last month
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LitEmotion group
This group will play to LitEmotion video game.
|
LitEmotion is a serious video game programmed for helping managing emotions.
The experimental group will play during 3 weeks while the control group will not play.
The sample will play during 21 days, one session daily, around 45 minutes.
After the 21 sessions the group will stop playing during 3 weeks.
Therefore, the scales are done three times.
In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
|
|
No Intervention: Control group
This group will no do receive any intervention with the video game
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health Assessment Questionnaire (HAQ)
Time Frame: Change from Baseline Independence Activities of the daily living up to 3 weeks
|
The HAQ evaluates the performance in the activities of daily living.
|
Change from Baseline Independence Activities of the daily living up to 3 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Change from Baseline Independence Activities of the daily living up to 3 weeks
|
The PSQI is an unreported measure which evaluate the quality of sleep.
|
Change from Baseline Independence Activities of the daily living up to 3 weeks
|
|
Fibromyalgia Impact Questionnaire (FIQ)
Time Frame: Change from Baseline Independence Activities of the daily living up to 3 weeks
|
The FIQ evaluates the quality of life in people with fibromyalgia.
|
Change from Baseline Independence Activities of the daily living up to 3 weeks
|
|
Spanish Pain Questionnaire (SPQ).
Time Frame: Change from Baseline Independence Activities of the daily living up to 3 weeks
|
The SPQ evaluates the kind of pain.
|
Change from Baseline Independence Activities of the daily living up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analogic scale (VAS)
Time Frame: Change from Baseline Independence Activities of the daily living up to 3 weeks
|
The VAS evaluates the level of pain.
|
Change from Baseline Independence Activities of the daily living up to 3 weeks
|
|
The spanish suggestibility inventory
Time Frame: Pre-assessment
|
This inventory evaluates the level of suggestibility.
|
Pre-assessment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Rivera J, Gonzalez T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004 Sep-Oct;22(5):554-60.
- Carmona, L. G., L.;Ballina, J.; Laffon, A. (2001). Proyecto EPISER 2000: prevalencia de las enfermedades reumáticas en la población española. Metodología, resultados del reclutamiento y características de la población. Revista Española de Reumatología, 28(1), 18-25.
- Esteve-Vives J, Rivera J, A Vallejo M; Grupo ICAF. [Assessment of functional capacity in fibromyalgia. Comparative analysis of construct validity of three functional scales]. Reumatol Clin. 2010 May-Jun;6(3):141-4. doi: 10.1016/j.reuma.2009.10.008. Epub 2010 Jan 27. Spanish.
- Leavitt F, Katz RS, Golden HE, Glickman PB, Layfer LF. Comparison of pain properties in fibromyalgia patients and rheumatoid arthritis patients. Arthritis Rheum. 1986 Jun;29(6):775-81. doi: 10.1002/art.1780290611.
- Rivera J, Alegre C, Ballina FJ, Carbonell J, Carmona L, Castel B, Collado A, Esteve JJ, Martinez FG, Tornero J, Vallejo MA, Vidal J. Documento de consenso de la Sociedad Espanola de Reumatologia sobre la fibromialgia. Reumatol Clin. 2006 Mar;2 Suppl 1:S55-66. doi: 10.1016/S1699-258X(06)73084-4. Epub 2008 Dec 10. No abstract available. Spanish.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IR 3/2018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.